Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
11.58
Nov 19 • 3:59 PM ET Dollar change-0.21 Percentage change(-1.78%)
Aftermarket Close
11.58
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
1.50B
Enterprise Value
612.19M
Income
-
Sales
-
Book/sh
7.95
Cash/sh
6.94
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
145
IPO
Apr 17, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.46
P/C
1.67
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
21.84
Current Ratio
21.84
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-
EPS next Y
-3.86
EPS next Q
-0.90
EPS this Y
-181.88%
EPS next Y
1.44%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-230.36%
Sales Q/Q
-
Insider Own
56.26%
Insider Trans
0.00%
Inst Own
46.04%
Inst Trans
53.73%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-10.25%
SMA50
-5.67%
SMA200
-33.82%
Trades
Shs Outstand
129.68M
Shs Float
56.80M
52W High
28.23 -58.98%
52W Low
9.76 18.65%
Volatility
6.64% 7.28%
ATR (14)
0.94
RSI (14)
40.87
Beta
-
Rel Volume
0.43
Avg Volume
1.09M
Volume
473,990
Perf Week
-12.34%
Perf Month
-10.37%
Perf Quarter
-32.56%
Perf Half Y
-45.07%
Perf YTD
-55.46%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
11.79
Price
11.58
Change %
-1.78%
Consensus
Strong Buy
Avg. Price Target
$43.00
Implied Upside
+271.3%
Analysts7incl. previous ratings
Rating Distribution7 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 09, 2026Initiated
CCanaccord Genuity
Buy$44+280.0%
May 12, 2026Initiated
WWilliam Blair
Outperform
May 12, 2026Initiated
TD logoTTD Cowen
Buy$57+392.2%
May 12, 2026Initiated
LLeerink Partners
Outperform$36+210.9%
May 12, 2026Initiated
JPM logoJJP Morgan
Overweight$30+159.1%
May 12, 2026Initiated
JEF logoJJefferies
Buy$48+314.5%
May 12, 2026Initiated
EVR logoEEvercore ISI
Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Renaud Ronald C JRCEO & PresidentJun 09 '26Option Exercise5.2538,094199,99438,094Jun 11 04:05 PM
RTW INVESTMENTS, LP10% OwnerApr 20 '26Buy16.00500,0008,000,00010,776,820Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC10% OwnerApr 20 '26Buy16.008,398,438134,375,00826,255,581Apr 20 06:10 PM
Koppel AdamDirectorApr 20 '26Buy16.001,562,50025,000,00022,583,268Apr 20 06:08 PM
Bain Capital Life Sciences Inv10% OwnerApr 20 '26Buy16.001,562,50025,000,00022,583,268Apr 20 06:01 PM
Kaplan Andrew T.DirectorApr 20 '26Buy16.008,398,438134,375,00826,255,581Apr 20 06:00 PM
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.
M.B.A.Mr. Ronald C. Renaud Jr.
M.S.Mr. Paul Douglas Burgess J.D.
Chief Commercial OfficerMs. Jamie Beth Coleman
Chief Financial OfficerMr. Douglas W. Pagan M.B.A.
Vice President of Corporate Communications & Investor RelationsMaura Gavaghan